Volume 87 Issue 19 | p. 17 | Concentrates
Issue Date: May 11, 2009

Ironwood Signs Pact With Spanish Firm

Department: Business

Ironwood Pharmaceuticals, based in Cambridge, Mass., has licensed to Spain's Laboratorios Almirall the European rights to develop and commercialize linaclotide, its investigational compound for irritable bowel syndrome. Almirall will pay $40 million up front plus potential precommercial licensing and milestone payments of up to $95 million. Ironwood would also receive royalties on sales in Europe.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment